{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=67",
    "query": {
      "condition": "Immune System Disorders",
      "page": 67
    },
    "page_size": 10
  },
  "pagination": {
    "page": 67,
    "page_size": 10,
    "total_count": 21019,
    "total_pages": 2102,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=68&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=66&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T03:13:00.107Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04275310",
      "title": "Microeconomic Intervention to Reduce HIV Transmission in Economically Disadvantaged Transgender Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hiv",
        "Transgenderism"
      ],
      "interventions": [
        {
          "name": "Microeconomic Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2022-07-20",
      "completion_date": "2022-11-17",
      "has_results": true,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04275310"
    },
    {
      "nct_id": "NCT02040623",
      "title": "Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "R348 Ophthalmic Solution, 0.2%",
          "type": "DRUG"
        },
        {
          "name": "R348 Ophthalmic Solution, 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 35,
      "start_date": "2014-03",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-10",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 2,
      "location_summary": "Plantation, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02040623"
    },
    {
      "nct_id": "NCT03397979",
      "title": "Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Infrequent versus Frequent Soaking Baths",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "MaineHealth",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 63,
      "start_date": "2011-11-14",
      "completion_date": "2017-03-21",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 1,
      "location_summary": "Portland, Maine",
      "locations": [
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03397979"
    },
    {
      "nct_id": "NCT04396496",
      "title": "Treatment of POEMS Syndrome With Daratumumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "POEMS Syndrome"
      ],
      "interventions": [
        {
          "name": "Daratumumab Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-09-22",
      "completion_date": "2023-10-16",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396496"
    },
    {
      "nct_id": "NCT00708227",
      "title": "Pharmacogenetics of b2-Agonists in Asthma.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2007-09",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708227"
    },
    {
      "nct_id": "NCT06152042",
      "title": "Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "BMF-219",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomea Fusion Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 37,
      "start_date": "2023-12-28",
      "completion_date": "2025-07-18",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 9,
      "location_summary": "North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more",
      "locations": [
        {
          "city": "North Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        },
        {
          "city": "Norman",
          "state": "Oklahoma"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06152042"
    },
    {
      "nct_id": "NCT00560391",
      "title": "Dasatinib in Combination With Revlimid (and Dexamethasone)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2008-05",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00560391"
    },
    {
      "nct_id": "NCT02652091",
      "title": "Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1b (Betaseron, BAY86-5046)",
          "type": "DRUG"
        },
        {
          "name": "BETACONNECT device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2016-02-05",
      "completion_date": "2017-09-13",
      "has_results": false,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 23,
      "location_summary": "Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652091"
    },
    {
      "nct_id": "NCT02481297",
      "title": "Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Lirilumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-06-23",
      "completion_date": "2019-08-15",
      "has_results": true,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481297"
    },
    {
      "nct_id": "NCT06979323",
      "title": "Depemokimab Asthma Imaging and Bronchoscopy Sub-Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Depemokimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2024-07-19",
      "completion_date": "2028-02-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-11-04T03:13:00.107Z",
      "location_count": 9,
      "location_summary": "Brooksville, Florida • Plantation, Florida • Kansas City, Kansas + 6 more",
      "locations": [
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06979323"
    }
  ]
}